199,630 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Bought by Van ECK Associates Corp

Van ECK Associates Corp purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 199,630 shares of the biotechnology company's stock, valued at approximately $3,424,000. Van ECK Associates Corp owned about 0.08% of ADMA Biologics at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in ADMA Biologics by 13.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock valued at $13,171,000 after buying an additional 80,400 shares during the period. Assenagon Asset Management S.A. raised its position in ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock worth $69,454,000 after acquiring an additional 92,281 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in ADMA Biologics during the 3rd quarter worth about $61,858,000. EWG Elevate Inc. purchased a new position in ADMA Biologics during the 4th quarter valued at about $480,000. Finally, Citigroup Inc. boosted its position in ADMA Biologics by 251.7% during the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock worth $7,741,000 after purchasing an additional 277,138 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Raymond James upped their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research report on Friday, November 8th. HC Wainwright increased their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th.

ADMA Biologics Trading Down 1.8 %

ADMA Biologics stock traded down $0.29 during mid-day trading on Friday, hitting $15.79. The stock had a trading volume of 966,301 shares, compared to its average volume of 2,255,241. The stock has a 50-day simple moving average of $17.03 and a two-hundred day simple moving average of $17.88. The stock has a market capitalization of $3.73 billion, a PE ratio of 56.32 and a beta of 0.75. ADMA Biologics, Inc. has a 12 month low of $5.08 and a 12 month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.